NASDAQ$BTTC

Black Titan Corp · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

Previous: $121K-100.0%
EPS (adj)

-$0.05

Previous: -$3.40+98.5%
Capital Expenditures

-$2K

No prior period
Free Cash Flow

-$2.25M

No prior period
Net Income

-$1.97M

Previous: -$2.57M+23.2%
Operating Income

-$1.93M

Previous: -$2.61M+26.0%
Gross Profit

-$3K

Previous: $51K-105.9%
Cash & Equivalents

$6.77M

Previous: $2.94M+130.6%
Total Assets

$8.09M

Previous: $4.06M+99.3%
R&D Expense

$487K

No prior period
Stock-Based Comp

$48K

Previous: -$91K+152.7%

Revenue & EPS history

Titan Pharmaceuticals · Revenue · Quarterly

$0

Q4 2023-100%vs Q4 2022
Beat estimate in 0 of 3 quarters(0%)
ActualEstimate

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro